. The dose determination for BEZ235 and cisplatin in the in vivo study. a Comparison of the activity of BEZ235 diluted in DMSO or the buffer with 0.5% methylcellulose and 0.1% Tween-80 in vitro. CL141 and H1975 cells were treated with 100 nM BEZ235 dissolved in DMSO or the buffer with 0.5% methylcellulose and 0.1% Tween-80 for 6 hours. Cell lysates were analyzed by Western blotting using the indicated antibodies. b BEZ235 (25 mg/kg or 45 mg/kg) was orally administered daily in mice bearing a subcutaneous CL141 cell xenograft tumor. N = 1 mouse per group. 25 mg/kg of BEZ235 was enough to suppress tumor growth and this dose also suited for combined treatment experiments c 2.5 mg/kg of cisplatin (CDDP) was intraperitoneally injected twice per week or 5 mg/kg of CDDP was injected once per week in mice bearing a subcutaneous CL141 xenograft tumor. N = 1 mouse per group. 2.5 mg/kg CDDP suppressed half of CL141 tumor growth while 5 mg/kg CDDP almost totally suppressed it. Then the condition, 2.5 mg/kg CDDP twice per week, was used for the combined treatment experiment. Ratio of cleaved PARP: 1 2.14 1 2.25 Figure S6 . BEZ235 synergistically enhances cisplatin-induced apoptosis in NSCLC cells. a CL141 cells were treated with the indicated concentrations of cisplatin and BEZ235, either alone or together, for 48 hours. Viability was analyzed using the WST-1 assay. The results of combined treatment were used to calculate the combination index (CI) and the CI values were shown in Fig. 5b . CL83 (b, c, f) and CL152 (d, e, g) cells were treated with the indicated concentrations of cisplatin and BEZ235, either alone or together, for 48 hours. Viability was analyzed using the WST-1 assay (b, d). The combination index was calculated as described in Materials and Methods (c, e). Levels of cleaved PARP, active caspase 3, LC3, and γ-H2A.X in cell lysates were analyzed by Western blotting (f, g). h CL141 cells were treated with 8 μM cisplatin and 100 nM BEZ235, either alone or together, for the indicated time. Levels of active caspase 3, γ-H2A.X, and β-actin in cell lysates were analyzed by Western blotting using the indicated antibodies. i H1975 and CL97 cells were treated with the indicated concentrations of cisplatin and BEZ235, either alone or together, for 48 hours. Levels of cleaved PARP, active caspase 3, and β-actin in cell lysates were analyzed by Western blotting. The related expression levels of protein, quantified by ImageJ as described in Materials and Methods, were shown below their corresponding blots. Figure S7 . BEZ235 synergistically enhances BIBW2992-induced apoptosis in EGFR-TKIresistant NSCLC cells. a H1975 cells were treated with the indicated concentrations of BIBW2992 and BEZ235, either alone or together, for 72 hours. Viability was analyzed using the WST-1 assay. The results of combined treatment were used to calculate the CI values, shown in Fig. 6b . b H1975 cells were treated as described in Figure 6c . Levels of the indicated proteins in cell lysates were analyzed by Western blotting using the indicated antibodies. c CL97 cells were treated with 100 nM BIBW2992 and BEZ235, either alone or together, for 48 hours. Levels of cleaved PARP, active caspase 3, cyclin D1/D3, phosphorylated Akt, phosphorylated p70S6K, phosphorylated 4EBP1, and β-actin in cell lysates were analyzed by Western blotting using the indicated antibodies.
